Your End-to-End Forum to Maximise the Therapeutic Index and Accelerate Your Journey from Concept to Approved Therapy

Antibody-drug conjugates remain front and centre of the biopharma world. Following Enhertu’s historic agnostic approval in HER2-positive solid tumours and TIVDAK winning full approval, the field has seen a surge in multi-billion-dollar acquisitions, commercialisation deals, and licensing agreements. These developments have enabled the ADC community to make strides in bringing these therapies to earlier-line treatments and expand their use to wider patient populations.

Returning for its 15th anniversary year, World ADC London is the leading European conference uniting over 1000 ADC enthusiasts to maximise the therapeutic index of ADCs. Whether you are brand new to the field or have over a decade of experience, work in discovery or manufacturing, hold a strategic position, or work day-to-day in the lab, this meeting offers something for you!

Don’t miss this chance to unlock unmissable R and D, focused industry networking opportunities, and emerging trends taking hold of the ADC field with sessions from 120+ world-leading speakers including Daiichi Sankyo, AstraZeneca, Pfizer, AbbVie, Merck, GSK, Johnson and Johnson, ADC Therapeutics and more.

URLs:
Website: https://go.evvnt.com/2688752-0?pid=11140
Brochure: https://go.evvnt.com/2688752-3?pid=11140

Prices:
Conference Only- Drug Developer Pricing: GBP 2719.00,
Conference + Workshop Day or Seminar Day- Drug Developer Pricing: GBP 3717.00,
Conference + Workshop Day + Seminar Day- Drug Developer Pricing: GBP 4715.00,
Conference Only- Academic Pricing: GBP 2319.00,
Conference + Workshop Day or Seminar Day- Academic Pricing: GBP 3117.00,
Conference + Workshop Day + Seminar Day- Academic Pricing: GBP 3915.00,
Conference Only- Service Provider Pricing: GBP 3319.00,
Conference + Workshop Day or Seminar Day- Service Provider Pricing: GBP 4817.00,
Conference + Workshop Day + Seminar Day- Service Provider Pricing: GBP 6315.00

Speakers: Alain Beck, Senior Director, Biologics Chemistry, Manufacturing and Controls Developability, Pierre Fabre, Alex Robertson, Executive Director, CMC Project Management, AstraZeneca, Dhiraj Gambhire, Global Clinical Lead, Enhertu, Executive Medical Director, Daiichi Sankyo, Garrett Cornelison, Senior Principal Scientist, Pfizer, Gavin Bennet, Senior Director, Drug Development, Bicycle Therapeutics, Greg Thurber, Associate Professor and Chair, Graduate Education, University of Michigan, Heidi Wang, Chief Executive Officer, OBI Pharma, Jiazhen Chen, Director, External Innovations, BioNTech, Joanna Opalinska, Senior Director of Clinical Development, GlaxoSmithKline, John Lambert, Independent Consultant and Honorary Professor, Queens University Belfast, Jon Travers, Senior Director, External Innovation and Early Development, Ipsen, Jutta Deckert, Vice President, Research and Development, Iksuda Therapeutics, Joseph Woolery, Vice President, Clinical Development, Zymeworks, Jutta Deckert, Vice President, Research and Development, Iksuda Therapeutics, Kerstin Hofer, Matrix and Science Lead, Roche, Kurt Pike, Senior Director, External Innovation, Johnson and Johnson, Marcel Rieker, Principal Scientist and Team Leader PROxAb Shuttle, Merck KGaA, Marisa Schmitt, Director, Bioanalysis, Heidelberg Pharma, Pavan Vajjah, Executive Director, Global Head ADC Clinical Pharmacology and Safety Sciences, AstraZeneca, Rakesh Dixit, President and Chief Executive Officer, Bionavigen Oncology, Robert Lutz, Chief Scientific Officer, Iksuda Therapeutics, Venkatesh Pilla, Reddy Senior Director, Global PKPD and Pharmacometrics, Eli Lilly, Xiaona Jing, Senior Vice President, Global Product Development and Partnering, Multitude Therapeutics

Time: 8:00 am to 5:00 pm